Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Clinical features of primary aldosteronism

INTRODUCTION

Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia.

Many subtypes of primary aldosteronism have been described since Conn's original report of the aldosterone-producing adenoma in 1954 [1-4]. The most common subtypes are:

  • Aldosterone-producing adenoma
  • Bilateral idiopathic hyperaldosteronism

Less common forms include:
To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Conn, JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med 1956; 97:135.
  2. Bravo, EL, Tarazi, RC, Dustan, HP, et al. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74:641.
  3. Mattsson, C, Young, WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198.
  4. Young, WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.
  5. August, JT, Nelson, DH, Thorn, GW. Response of normal subjects to large amounts of aldosterone. J Clin Invest 1958; 37:1549.
  6. Gonzalez-Campoy, JM, Romero, JC, Knox, FG. Escape from the sodium-retaining effects of mineralocorticoids: Role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.
  7. Hall, JE, Granger, JP, Smith, MJ Jr, Premen, AJ. Role of renal hemodynamics and arterial pressure in aldosterone "escape". Hypertension 1984; 6:I183.
  8. Yokota, N, Bruneau, BG, Kuroski de Bold, ML, de Bold, AJ. Atrial natriuretic factor contributes to mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994; 94:1938.
  9. Wang, XY, Masilamani, S, Nielsen, J, et al. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 2001; 108:215.
  10. Guyton, AC. Blood pressure control — Special role of the kidneys and body fluids. Science 1991; 252:1813.
  11. Kinoshita, Y, Knox, FG. Role of prostaglandins in proximal tubular sodium reabsorption: Response to elevated renal interstitial hydrostatic pressure. Circ Res 1989; 64:1013.
  12. Clore, J, Schoolwerth, A, Watlington, CO. When is cortisol a mineralocorticoid? Kidney Int 1992; 42:1297.
  13. Pedrinelli, R, Bruschi, G, Graziadei, L, et al, Dietary sodium change in primary hyperaldosteronism. Atrial natriuretic factor, hormonal, and vascular responses. Hypertension 1988; 12:192.
  14. Blumenfeld, JD, Sealey, JE, Schlussel, Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877.
  15. Zarifis, J, Lip, GYH, Leatherdale, B, Beevers, G. Malignant hypertension in association with primary aldosteronism. Blood Press 1996; 5:250.
  16. Douma, S, Petidis, K, Doumas, M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.
  17. Vantyghem, MC, Ronci, N, Provost, F, et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141:279.
  18. Vasan, RS, Evans, JC, Larson, MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33.
  19. Young, DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.
  20. George, JM, Wright, L, Bell, NH, Bartter, FC. The syndrome of primary aldosteronism. Am J Med 1970; 48:343.
  21. Mulatero, P, Stowasser, M, Loh, KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045.
  22. Fraser, R, Murray, GD, Connell, JM. Conn's syndrome: no longer a needle in a haystack?. Clin Endocrinol (Oxf) 1998; 49:709.
  23. Loh, KC, Koay, ES, Khaw, MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854.
  24. Litchfield WR, Coolidge, C, Silva, P, et al. Impaired potassium-stimulated aldosterone production: A possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82:1507.
  25. Rossi, GP, Bernini, G, Caliumi, C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293.
  26. Gregoire, JR. Adjustment of the osmostat in primary aldosteronism. Mayo Clin Proc 1994; 69:1108.
  27. Quamme, GA. Control of magnesium transport in the thick ascending limb. Am J Physiol 1989; 256:F197.
  28. Ribstein, J, Du Cailar, G, Fesler, P, Mimran, A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16:1320.
  29. Sechi, LA, Novello, M, Lapenna, R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295:2638.
  30. Shigematsu, Y, Hamada, M, Okayama, H, et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29:723.
  31. Rossi, GP, Sacchetto, A, Visentin, P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039.
  32. Yoshihara, F, Nishikimi, T, Yoshitomi, Y, et al. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996; 9:523.
  33. Milliez, P, Girerd, X, Plouin, PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243.
  34. Catena, C, Colussi, G, Nadalini, E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80.
  35. Pitt, B, Zannad, F, Remme, WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709.
  36. Pitt, B, Remme, W, Zannad, F, Neaton, J. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.
  37. Williams, JS, Williams, GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88:2364.
  38. Young, WF Jr. Minireview: primary aldosteronism -- changing concepts in diagnosis and treatment. Endocrinology 2003; 144:2208.
  39. Jaffe, IZ, Mendelsohn, ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643.
  40. Leopold, JA, Dam, A, Maron, BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13:189.
white circle LOG IN
white circle DEMO